Drug Profile
Research programme: chimeric antigen receptor T cell therapy - Eureka Therapeutics
Alternative Names: Armored CAR; Armored T-cell; ET 1501; ET 1502; ET 1504; ET1501/NY-ESO-1; TCR mimic antibody therapeutics - Eureka Therapeutics; TCRm antibody therapeutics - Eureka TherapeuticsLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Eureka Therapeutics
- Developer Eureka Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Mesothelioma
- No development reported Cervical cancer; Haematological malignancies; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)
- 21 Jun 2022 Early research in Mesothelioma in USA (Parenteral) (Eureka Therapeutics pipeline, June 2022)